Do analysts prefer ENGN or BCTX?

enGene currently has a consensus price target of $11.05, indicating a potential upside of 513.64%. Given enGene's stronger consensus rating and higher possible upside, equities analysts plainly believe enGene is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 2 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.14 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ENGN or BCTX?

enGene is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$1.13 N/A Briacell Therap N/A N/A -$26.31M -$7.92 N/A

Is ENGN or BCTX more profitable?

enGene's return on equity of -27.97% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -27.97% -22.65% Briacell Therap N/A -153.53% -129.26%

Does the media favor ENGN or BCTX?

In the previous week, enGene had 24 more articles in the media than Briacell Therap. MarketBeat recorded 27 mentions for enGene and 3 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.30 beat enGene's score of 0.28 indicating that Briacell Therap is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 3 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BCTX or TLSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, BCTX or TLSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is BCTX or TLSA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Tiziana Life Sciences N/A N/A N/A

Does the media refer more to BCTX or TLSA?

In the previous week, Briacell Therap and Briacell Therap both had 3 articles in the media. Tiziana Life Sciences' average media sentiment score of 0.63 beat Briacell Therap's score of 0.30 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CBUS or BCTX?

Cibus presently has a consensus price target of $9.00, suggesting a potential upside of 473.25%. Given Cibus' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cibus is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cibus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CBUS or BCTX more profitable?

Briacell Therap has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Briacell Therap's return on equity of -153.53% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,258.89% -287.03% -27.99% Briacell Therap N/A -153.53% -129.26%

Does the media favor CBUS or BCTX?

In the previous week, Briacell Therap had 1 more articles in the media than Cibus. MarketBeat recorded 3 mentions for Briacell Therap and 2 mentions for Cibus. Cibus' average media sentiment score of 0.93 beat Briacell Therap's score of 0.30 indicating that Cibus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cibus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BCTX or BNR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer BCTX or BNR?

In the previous week, Burning Rock Biotech had 2 more articles in the media than Briacell Therap. MarketBeat recorded 5 mentions for Burning Rock Biotech and 3 mentions for Briacell Therap. Burning Rock Biotech's average media sentiment score of 0.63 beat Briacell Therap's score of 0.30 indicating that Burning Rock Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BCTX or BDTX?

Black Diamond Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 417.68%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Is BCTX or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% Black Diamond Therapeutics N/A -32.10% -25.21%

Does the media refer more to BCTX or BDTX?

In the previous week, Briacell Therap and Briacell Therap both had 3 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.45 beat Briacell Therap's score of 0.30 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Briacell Therap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Black Diamond Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Briacell Therap (BCTX) Competitors

$3.63 +0.03 (+0.83%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.66 +0.04 (+0.96%)

As of 09/11/2026 07:54 PM Eastern

Compare

BCTX vs. ENGN, TLSA, CBUS, BNR, and BDTX

Should you buy Briacell Therap stock or one of its competitors? Briacell Therap's main competitors and comparable companies include enGene (ENGN), Tiziana Life Sciences (TLSA), Cibus (CBUS), Burning Rock Biotech (BNR), and Black Diamond Therapeutics (BDTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Briacell Therap compare to enGene?

enGene (NASDAQ:ENGN) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, enGene had 24 more articles in the media than Briacell Therap. MarketBeat recorded 27 mentions for enGene and 3 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 0.30 beat enGene's score of 0.28 indicating that Briacell Therap is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	3 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.2% of enGene shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 0.7% of Briacell Therap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

enGene has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

enGene currently has a consensus price target of $11.05, indicating a potential upside of 513.64%. Given enGene's stronger consensus rating and higher possible upside, equities analysts plainly believe enGene is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

enGene is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$1.13	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

enGene's return on equity of -27.97% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-27.97%	-22.65%
Briacell Therap	N/A	-153.53%	-129.26%

Summary

enGene beats Briacell Therap on 9 of the 12 factors compared between the two stocks.

How does Briacell Therap compare to Tiziana Life Sciences?

Briacell Therap (NASDAQ:BCTX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Tiziana Life Sciences' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Briacell Therap and Briacell Therap both had 3 articles in the media. Tiziana Life Sciences' average media sentiment score of 0.63 beat Briacell Therap's score of 0.30 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Briacell Therap has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

15.4% of Briacell Therap shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tiziana Life Sciences beats Briacell Therap on 7 of the 9 factors compared between the two stocks.

How does Briacell Therap compare to Cibus?

Cibus (NASDAQ:CBUS) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

33.8% of Cibus shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 29.9% of Cibus shares are held by company insiders. Comparatively, 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cibus has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Briacell Therap has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Briacell Therap's return on equity of -153.53% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Briacell Therap	N/A	-153.53%	-129.26%

Cibus presently has a consensus price target of $9.00, suggesting a potential upside of 473.25%. Given Cibus' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cibus is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Briacell Therap had 1 more articles in the media than Cibus. MarketBeat recorded 3 mentions for Briacell Therap and 2 mentions for Cibus. Cibus' average media sentiment score of 0.93 beat Briacell Therap's score of 0.30 indicating that Cibus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cibus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Briacell Therap has lower revenue, but higher earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	32.97	-$127.08M	-$1.65	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Summary

Cibus beats Briacell Therap on 10 of the 14 factors compared between the two stocks.

How does Briacell Therap compare to Burning Rock Biotech?

Briacell Therap (NASDAQ:BCTX) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Burning Rock Biotech has higher revenue and earnings than Briacell Therap. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Burning Rock Biotech	$77.16M	1.67	-$7.92M	-$0.87	N/A

Briacell Therap has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Burning Rock Biotech has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Briacell Therap has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -13.60%. Burning Rock Biotech's return on equity of -12.98% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Burning Rock Biotech	-13.60%	-12.98%	-8.59%

In the previous week, Burning Rock Biotech had 2 more articles in the media than Briacell Therap. MarketBeat recorded 5 mentions for Burning Rock Biotech and 3 mentions for Briacell Therap. Burning Rock Biotech's average media sentiment score of 0.63 beat Briacell Therap's score of 0.30 indicating that Burning Rock Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Burning Rock Biotech beats Briacell Therap on 10 of the 12 factors compared between the two stocks.

How does Briacell Therap compare to Black Diamond Therapeutics?

Briacell Therap (NASDAQ:BCTX) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Black Diamond Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 417.68%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Briacell Therap has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.31, suggesting that its stock price is 231% more volatile than the broader market.

Black Diamond Therapeutics has higher revenue and earnings than Briacell Therap. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
Black Diamond Therapeutics	$70M	1.63	$22.37M	-$0.75	N/A

Black Diamond Therapeutics' return on equity of -32.10% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

In the previous week, Briacell Therap and Briacell Therap both had 3 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.45 beat Briacell Therap's score of 0.30 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Diamond Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Black Diamond Therapeutics beats Briacell Therap on 12 of the 13 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCTX vs. The Competition

Export

Metric	Briacell Therap	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.58M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.46	8.41	214.39	20.85
Price / Sales	N/A	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.39	15.12	10.33	6.21
Net Income	-$26.31M	-$22.86M	$3.50B	$358.54M
7 Day Performance	1.68%	-4.34%	-3.32%	-2.35%
1 Month Performance	5.52%	0.54%	-0.53%	-3.23%
1 Year Performance	-54.63%	40.74%	23.51%	8.79%

Briacell Therap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCTX Briacell Therap	0.3705 of 5 stars	$3.63 +0.8%	N/A	-54.6%	$31.58M	N/A	N/A	8	Short Interest Increase Gap Up
ENGN enGene	4.0788 of 5 stars	$1.86 -3.4%	$11.05 +495.4%	-68.5%	$124.27M	N/A	N/A	31	Trending News Earnings Report Analyst Forecast Analyst Revision
TLSA Tiziana Life Sciences	1.4478 of 5 stars	$0.97 -2.0%	N/A	-43.2%	$123.44M	N/A	N/A	8	News Coverage Upcoming Earnings
CBUS Cibus	1.6003 of 5 stars	$1.60 -0.9%	$9.00 +464.3%	+15.4%	$122.29M	$3.64M	N/A	48
BNR Burning Rock Biotech	0.9425 of 5 stars	$11.70 +9.2%	N/A	+44.6%	$121.99M	$514.43M	N/A	1,390	News Coverage Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCTX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Briacell Therap (BCTX) Competitors

BCTX vs. ENGN, TLSA, CBUS, BNR, and BDTX

How does Briacell Therap compare to enGene?

Summary

How does Briacell Therap compare to Tiziana Life Sciences?

Summary

How does Briacell Therap compare to Cibus?

Summary

How does Briacell Therap compare to Burning Rock Biotech?

Summary

How does Briacell Therap compare to Black Diamond Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Briacell Therap (BCTX) Competitors

BCTX vs. ENGN, TLSA, CBUS, BNR, and BDTX

How does Briacell Therap compare to enGene?

Does the media favor ENGN or BCTX?

Do insiders and institutionals believe in ENGN or BCTX?

Which has more risk and volatility, ENGN or BCTX?

Do analysts prefer ENGN or BCTX?

Which has stronger valuation and earnings, ENGN or BCTX?

Is ENGN or BCTX more profitable?

Summary

How does Briacell Therap compare to Tiziana Life Sciences?

Is BCTX or TLSA more profitable?

Does the media refer more to BCTX or TLSA?

Which has preferable valuation & earnings, BCTX or TLSA?

Which has more risk and volatility, BCTX or TLSA?

Do insiders & institutionals hold more shares of BCTX or TLSA?

Do analysts rate BCTX or TLSA?

Summary

How does Briacell Therap compare to Cibus?

Do institutionals and insiders believe in CBUS or BCTX?

Which has more volatility and risk, CBUS or BCTX?

Is CBUS or BCTX more profitable?

Do analysts rate CBUS or BCTX?

Does the media favor CBUS or BCTX?

Which has higher valuation and earnings, CBUS or BCTX?

Summary

How does Briacell Therap compare to Burning Rock Biotech?

Do institutionals & insiders hold more shares of BCTX or BNR?

Which has better valuation and earnings, BCTX or BNR?

Which has more volatility & risk, BCTX or BNR?

Do analysts recommend BCTX or BNR?

Is BCTX or BNR more profitable?

Does the media prefer BCTX or BNR?

Summary

How does Briacell Therap compare to Black Diamond Therapeutics?

Do analysts prefer BCTX or BDTX?

Which has more volatility & risk, BCTX or BDTX?

Which has better earnings and valuation, BCTX or BDTX?

Is BCTX or BDTX more profitable?

Does the media refer more to BCTX or BDTX?

Do institutionals and insiders hold more shares of BCTX or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools